Home Newsfeeds Apple Ends Consulting Agreement With Jony Ive, Its Former Design Leader

Apple Ends Consulting Agreement With Jony Ive, Its Former Design Leader

-NY Times https://www.nytimes.com/2022/07/12/technology/apple-jony-ive-end-agreement.html

byCharles Gross

July 13, 2022

1 minute read

-NY Times

https://www.nytimes.com/2022/07/12/technology/apple-jony-ive-end-agreement.html

HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Lowers Price Target to $46

By Benzinga Newsdesk

August 9, 6:22 AM

HC Wainwright & Co. analyst Robert Burns maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and lowers the price target from $47 to $46.

RLAY

After Apple, India Eyes Plum EV Maker Tesla To Migrate Production

By Anusuya Lahiri

July 24, 9:33 AM

Tesla, Inc (NASDAQ: TSLA) representatives will likely meet India's commerce minister in July to discuss plans to build a

AAPL

U.S. Department Of Veterans Affairs Awards Acentra Health, Backed By Carlyle, $52.3M Financial Services Center Contract For Claims Adjudication, Provider Access, Data Analytics And Visualization

By Benzinga Newsdesk

October 3, 8:23 AM

The U.S. Department of Veterans Affairs (VA) has awarded Acentra Health (formerly CNSI) a three-year, $52.3 million contract to support claims adjudication, provider access, data analytics, and visualization for its

Uncertainties In Nevro’s Core Business Lead To Revised FY24 Projections By Oppenheimer Analyst

By Nabaparna Bhattacharya

June 6, 2:56 PM

Oppenheimer analyst Suraj Kalia reiterated an Outperform rating on the shares of Nevro Corp. (NYSE:NVRO), with a price target of $40. Nevro…

NVRO

Apple Ends Consulting Agreement With Jony Ive, Its Former Design Leader

Related Posts

HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Lowers Price Target to $46

After Apple, India Eyes Plum EV Maker Tesla To Migrate Production

U.S. Department Of Veterans Affairs Awards Acentra Health, Backed By Carlyle, $52.3M Financial Services Center Contract For Claims Adjudication, Provider Access, Data Analytics And Visualization

Uncertainties In Nevro’s Core Business Lead To Revised FY24 Projections By Oppenheimer Analyst